Preview

Медицинская генетика

Расширенный поиск

Синдром Линча. Современное состояние проблемы

Полный текст:

Аннотация

Синдром Линча - наследственный синдром, вызванный герминальной мутацией в одном из генов системы репарации неспаренных оснований ДНК, обусловливающий высокий риск развития рака толстой кишки, а также других органов. В обзоре представлены клинико-генетические характеристики пациентов с синдромом Линча, а также рассмотрены вопросы диагностики, хирургических и химиотерапевтических мероприятий у такого рода больных.

Об авторах

А. С. Цуканов
Государственный научный центр колопроктологии им. А.Н. Рыжих
Россия


Ю. А. Шелыгин
Государственный научный центр колопроктологии им. А.Н. Рыжих
Россия


Д. А. Семенов
Государственный научный центр колопроктологии им. А.Н. Рыжих
Россия


Д. Ю. Пикунов
Государственный научный центр колопроктологии им. А.Н. Рыжих
Россия


А. В. Поляков
Медико-генетический научный центр
Россия


Список литературы

1. Warthin AS. Heredity with reference to carcinoma. Arch Intern Med. 1913; 12: 546-555.

2. Семенов ДА, Ачкасов СИ, Цуканов АС, Сушков ОИ. Синдром Линча. От «семьи G» до ДНК-диагностики. Колопроктология. 2014; (3):57-61.

3. Lynch HT, Kimberling W, Albano WA et al. Hereditary non-polyposis colorectal cancer (Lynch syndromes I and II). Clinical description of resource. Cancer 1985; 56(4):934-38.

4. Giardiello FM, Allen JI, Axilband JE et al. Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. 2014 Aug;57(8):1025-48.

5. Moreira L, Balaguer F, Lindor N et al. EPICOLON Consortium. Identification of Lynch Syndrome Among Patients With Colorectal Cancer. 2012 Oct 17;308(15):1555-65.

6. Perez-Cabornero L, Infante M, Velasco E et al. Genotype-phenotype correlation in MMR mutation-positive families with Lynch syndrome. Int J Colorectal Dis. 2013 Sep;28(9):1195-201.

7. Win AK, Parry S, Parry B et al. Risk of metachronous colorectal cancer following surgery for rectal cancer in mismatch repair gene mutation carriers, Ann Surg Oncol. 2013 Jun;20(6):1829-36.

8. Gryfe R, Kim H, Hsieh E et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000 Jan 13;342(2):69-77.

9. Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol. 2012 Dec 10;30(35):4409-15.

10. Watson P, Vasen H, Mecklin J et al. The risk of extra-colonic, extra-endometrial cancer in Lynch syndrome. Int J Cancer. 2008 Jul 15;123(2):444-9.

11. Raymond V, Mukherjee B, Wang F et al. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol. 2013 May 10;31(14):1713-8.

12. Lynch H, Lynch P, Pester J et al. The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre’s syndrome. Arch Intern Med. 1981 Apr;141(5):607-11.

13. Hamilton S., Liu B., Parsons R. et al. The molecular basis of Turcot`s syndrome. N Engl J Med. 1995 Mar 30;332(13):839-47.

14. Gruber S. New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. Gastroenterology. 2006 Feb;130(2):577-87.

15. Peltomaki P. Update on Lynch syndrome genomics. Fam Cancer. 2016 Jul;15(3):385-93.

16. Rahner N, Steinke V, Schlegelberger B et al. Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2). Eur J Hum Genet. 2010 Sep;18(9).

17. Tutlewska K, Lubinski J, Kurzawski G. Germline deletions in the EPCAM gene as a cause of Lynch syndrome: literature review. 2013 Aug 12;11(1):9.

18. Geiersbach K, Samowitz W. Microsatellite instability and colorectal cancer. 2011 Oct;135(10):1269-77.

19. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):191-5.

20. Vasen H, Moslein G, Alonso A et al. Guidelines for the clinical management of Lynch syndrome (hereditary nonpolyposis cancer). Med Genet. 2007 Jun;44(6):353-62.

21. Boland CR, Shike M. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology. 2010 Jun;138(7):2197.e1-7.

22. Stoffel EM, Syngal S. Adenomas in young patients: what is the optimal evaluation? Am J Gastroenterol. 2005 May;100(5):1150-3.

23. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. 1998 Nov 15;58(22):5248-57.

24. Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. 2002 Dec;123(6):1804-11.

25. Wu Y, Berends M, Mensink R et al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet. 1999 Nov;65(5):1291-8.

26. Berg A, Armstrong K, Botkin J et al. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009 Jan;11(1):35-41.

27. Weissman S, Burt R, Church J, et al. Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline. 2012 Aug;21(4):484-93.

28. Plazzer JP, Sijmons RH, Woods MO et al. (2013) The InSiGHT database: utilizing 100 years of insights into Lynch syndrome. 2013 Jun;12(2):175-80.

29. Win AK, Jenkins MA, Buchanan DD et al. Determining the frequency of de novo germline mutations in DNA mismatch repair genes. J Med Genet. 2011 Aug;48(8):530-4.

30. Froggatt NJ, Green J, Brassett C et al. A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. 1999 Feb;36(2):97-102.

31. Desai DC, Lockman JC, Chadwick RB et al. Recurrent germline mutation in MSH2 arises frequently de novo. 2000 Sep;37(9):646-52.

32. Ponti G, Castellsague E, Ruini C et al. Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome. 2015 Jun;87(6):507-16.

33. Vasen H, Mecklin J, Khan P et al. The international Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer. Dis Colon Rectum. 1991 May;34(5):424-5.

34. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999 Jun;116(6):1453-6.

35. Green R, Parfrey P,Woods M et al. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):331-40.

36. Hampel H, Frankel W, Martin E et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005 May 5;352(18):1851-60.

37. Perez-Carbonell L, Ruiz-Ponte C, Guarinos C et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut. 2012 Jun;61(6):865-72.

38. Цуканов АС, Поспехова НИ, Шубин ВП и соавт. Дифференциальный диагноз синдрома Линча от других форм неполипозного колоректального рака среди российских пациентов. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014; (24):78-84.

39. Kastrinos F, Allen J, Stockwell D et al. Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. 2009 Jun;104(6):1508-18.

40. Siegel R, Naishadham D, Jemal A Cancer Statistics, 2013. CA Cancer J Clin. 2013 Jan;63(1):11-30.

41. Jarvinen H, Renkonen-Sinisalo L, Aktan-Collan K et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol. 2009 Oct 1;27(28):4793-7.

42. Stuckless S., Green J., Dawson L. et al. Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation. 2013 Apr;83(4):359-64.

43. Renkonen-Sinisalo L, Sipponen P, Aarnio M, et al. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. 2002 May;37(5):574-7.

44. Barrow E., Robinson L., Alduaij W. et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations, Clin Genet. 2009 Feb;75(2):141-9.

45. Winkels RM , Botma A , Van Duijnhoven FJ et al. Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome. Gastroenterology. 2012 Feb;142(2):241-7.

46. Botma A, Nagengast FM, Braem MG et al. Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study. 2010 Oct 1;28(28):4346-53.

47. Burn J, Mathers J, Bishop DT. Lynch syndrome: history, causes, diagnosis, treatment and prevention (CAPP2 trial) Dig Dis. 2012;30 Suppl 2:39-47.

48. Burn J, Mathers J, Bishop D. Chemoprevention in Lynch syndrome. Fam Cancer. 2013 Dec;12(4):707-18.

49. Koopman M, Kortman GA, Mekenkamp L et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. 2009 Jan 27;100(2):266-73.

50. Fischer F, Baerenfaller K, Jiricny J. 5-fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology. 2007 Dec;133(6):1858-68.

51. Fink D., Zheng H., Nebel S. et al. In vitro and in vivo resistance to cisplatine in cells that have lost DNA mismatch repair. Cancer Res. 1997 May 15;57(10):1841-5.

52. Jacob S, Aguado M, Fallik D, Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res. 2001 Sep 1;61(17):6555-62.

53. Guastadisegni C., Colafranceschi M., Ottini L. et al. Microsatellite instability as a marker of prognosis and response to therapy: meta-analysis of colorectal cancer survival data. 2010 Oct;46(15):2788-98.

54. Kim GP, Colangelo LH, Wieand HS et al. Prognostic and predictive roles of highdegree highdegree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. 2007 Mar 1;25(7):767-72.

55. Vilar E, Scaltriti M, Balmana J et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicityto irinotecan in human colorectal cancer cell lines. Br J Cancer. 2008 Nov 18;99(10):1607-12.

56. Zaanan A, Cuilliere-Dartigues P, Guilloux A et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. 2010 Apr;21(4):772-80.

57. Bertagnolli MM, Niedzwiecki D, Compton CC et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009 Apr 10;27(11):1814-21.

58. Le D, Uram J, Wang H et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency 2015 Jun 25;372(26):2509-20.

59. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Clin Oncol. 2014 Apr 1;32(10):1020-30.


Для цитирования:


Цуканов А.С., Шелыгин Ю.А., Семенов Д.А., Пикунов Д.Ю., Поляков А.В. Синдром Линча. Современное состояние проблемы. Медицинская генетика. 2017;16(2):11-18.

For citation:


Tsukanov A.S., Shelygin Y.A., Semenov D.A., Pikunov D.Y., Polyakov A.V. Lynch syndrome: current status. Medical Genetics. 2017;16(2):11-18. (In Russ.)

Просмотров: 584


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2073-7998 (Print)